CHANGEBLOCK
27.11.2023 11:32:27 CET | Business Wire | Press release
Changeblock, a global sustainability fintech company utilizing advanced data-systems and technologies to accelerate planet repair and protection activities through the generation and exchange trading of high-integrity environmental assets, such as carbon credits, today announced the appointment of Baroness Evans of Bowes Park, former leader of the UK House of Lords, as Senior Advisor, Policy & Ethics.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231123431705/en/
Baroness Natalie Evans of Bowes Park, former UK Cabinet Minister as Leader of the House of Lords and Senior Advisor, Policy and Ethics of Changeblock Limited. (Photo: Business Wire)
Trust and integrity are crucial for companies to monetize their planet repair and protect initiatives, and therefore crucial for credits to be adopted at the scale necessary towards achieving net-zero, Consequently, policy and ethics are major focus areas for Changeblock that require integration into the credit value chain. The appointment of Baroness Evans will significantly strengthen the Company’s efforts in this regard, and augments the work already being done with multiple standard and verification agencies.
Baroness Evans commented, “Reducing society’s environmental footprint is one of the most pressing challenges we as humanity are facing today, and tradeable offsets, such as credits, hold great promise towards delivering this. Their effectiveness will be impacted by how the companies in this eco-system engage with policy and policy makers.
“Ethics play an increasingly important role in credit integrity assessments and in investment decision making. Changeblock’s forward, strategic thinking, combined with their unique offering that meets such a critical need, make this an exciting opportunity. I look forward to working with Billy and the team and help Changeblock cement its leadership position as a critical net-zero infrastructure partner.”
Billy Richards, Changeblock CEO, stated, “We believe Baroness Evans is exceptionally well positioned to provide Changeblock with actionable insights, and help us strengthen our position as a critical infrastructure partner for credit generators, off-setters, investors and policy makers. I believe this appointment reflects the importance, integrity and quality of our offering, as well as the depth and strength of our network, and I am excited to be working on these important initiatives with Natalie as we expand our operations and help smooth the path to net-zero.”
Baroness Evans
Baroness Evans of Bowes Park is a Conservative member of the House of Lords. She was appointed a life peer in October 2014, and acted as Leader of the House of Lords and a member of the UK Government’s Cabinet from 2016 to 2022 - the longest serving Leader for 70 years. Between 2015 and 2016 she was a junior Government minister in the Department of Education, Department for Work and Pensions, and the Ministry of Justice. Before entering the Lords, Natalie held a variety of senior positions including CEO of the New Schools Network, Deputy Director of Policy Exchange, and Head of Policy at the British Chambers of Commerce.
Changeblock at COP28
Billy Richards and Baroness Natalie Evans from Changeblock will attend COP28 in Dubai. Changeblock is hosting a roundtable with leaders like David Greenall (KPMG), Jim Andrew (Pepsico), and Michael Terrell (Google), discussing AI analytics in carbon offsetting. The roundtable, titled “The Critical Role of Integrity in Carbon Credits and Offsets for Effective Planet Repair,” will explore sustainable carbon mitigation strategies.
About Changeblock
Changeblock creates global markets that make the creation and trade of environmental assets for individuals, businesses, and governments easy, affordable, transparent, secure, and environmentally responsible. The company is led by professionals with deep expertise in technology and environmental credits with a proven track record in building and delivering solutions that work in the real world, including members of the team that created the first carbon credit, and come from top global organisations.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231123431705/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 15:00:00 CEST | Press release
Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release
Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
